Welcome to another insightful session of “Ask the Author”! Today, we are thrilled to host Professor Mazen Noureddin, who will delve into the groundbreaking findings from the “Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis,” recently published in the New England Journal of Medicine (June 2024).

Congratulations to Professor Noureddin and Co-Authors

Before we dive into the details, let’s extend our congratulations to Professor Noureddin and his team for their significant contributions to this pivotal study.

Context and Design of the Study

Professor Noureddin explains the context behind their research, highlighting MASH (Metabolic Associated Fatty Liver Disease) as a growing concern globally. The study focused on Survodutide, a dual GLP-1 glucagon agonist, known for its potential in weight loss and direct effects on liver health. The randomized controlled trial spanned two years, aiming to assess its efficacy in patients with NASH scores of four or higher and fibrosis stages ranging from F1 to F3.

Key Findings

The study featured four arms, including varying doses of Survodutide and a placebo. Results were compelling, with significant percentages of patients experiencing MASH improvement without worsening fibrosis, particularly notable in higher doses compared to placebo. Secondary endpoints such as MRI-PDFF showed promising improvements in liver fat content, reinforcing the drug’s potential in treating metabolic liver diseases.

Survodutide’s Differentiation and Future Implications

Professor Noureddin discusses how Survodutide stands out among other drugs in development for MASH treatment. Unlike some metabolic drugs that primarily induce weight loss, Survodutide demonstrated concurrent improvements in MASH resolution and fibrosis reduction, setting a promising precedent for its phase 3 trials.

Looking Ahead

Reflecting on the broader landscape of MASH treatment, Professor Noureddin emphasizes the optimism surrounding GLP-1 and glucagon-based therapies. He highlights ongoing developments with other promising drugs and anticipates a brighter future for effective MASH management.

Conclusion

This session with Professor Mazen Noureddin provides a compelling glimpse into the evolving field of MASH treatment. His insights into Survodutide’s efficacy and future prospects underscore its potential to transform clinical practice.

Stay tuned for more updates and in-depth discussions on emerging therapies in our ongoing “Ask the Author” series.

Aujourd’hui, plongez au cœur de l’avancée médicale la plus prometteuse pour la stéatohépatite métabolique dans notre toute nouvelle vidéo “Demander à l’auteur”. Nous avons eu l’honneur d’accueillir le Professeur Jérôme Boursier, chef de service à Angers et éminent spécialiste de cette maladie en plein essor.

Dans cette session captivante, le Professeur Boursier présente l’étude SYNERGY-NASH, récemment publiée dans le prestigieux New England Journal of Medicine. Cette étude révolutionnaire explore l’efficacité du tirzépatide, un analogue des incrétines, dans le traitement de la stéatohépatite métabolique.

Pourquoi regarder cette vidéo ?

• Des résultats impressionnants : Découvrez comment le tirzépatide a permis à jusqu’à 62% des patients d’atteindre la résolution de la stéatohépatite sans aggravation de la fibrose, avec un effet dose démontré.
• Impact global sur la santé : En plus de son efficacité sur le foie, le tirzépatide a montré des effets bénéfiques sur la perte de poids, les transaminases, la stéatose hépatique, et même le profil glycémique des patients diabétiques.
• Sécurité et accessibilité : Explorez les implications pratiques de ces résultats, notamment sur la gestion des effets secondaires et la disponibilité actuelle du tirzépatide dans certains pays.

Ne manquez pas cette opportunité unique de vous informer sur les avancées les plus récentes dans le domaine de la stéatohépatite métabolique. Regardez la vidéo complète pour entendre directement du Professeur Boursier comment cette nouvelle classe thérapeutique pourrait transformer la prise en charge des patients.

Restez à l’affût pour plus d’informations sur nos prochaines sessions “Demander à l’auteur” où nous explorerons encore davantage les avancées médicales qui façonnent l’avenir de la médecine.

Regardez la vidéo dès maintenant et plongez dans l’avenir du traitement de la stéatohépatite !

Ce post de blog met en avant les principaux points de l’interview avec le Professeur Jérôme Boursier, en mettant l’accent sur les résultats de l’étude SYNERGY-NASH et l’impact potentiel du tirzépatide dans le traitement de la stéatohépatite métabolique.

Welcome to a new insightful episode of “Ask the Author”. Today, we’re honored to have Professor Vincent Wong with us, discussing his groundbreaking work titled “Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease,” recently published in JAMA.

In this enlightening discussion, Professor Wong delves into the background and context of their study. He highlights the prevalence of Metabolic Associated Fatty Liver Disease (MAFLD), affecting over 30% of the global population, necessitating the use of noninvasive tests (NITs) for disease assessment. Unlike previous studies focused solely on the correlation between NITs and liver histology, Professor Wong’s team aimed to demonstrate the prognostic value of NITs in monitoring disease progression and treatment response.

Their study, a multicenter cohort involving over 16,000 patients with MAFLD, showcased impressive numbers. Prospective data collection across 16 tertiary referral centers allowed for longitudinal analysis, with more than 10,000 patients undergoing multiple examinations. This comprehensive approach provided insights into the prognostic significance of changes in NITs over time.

The results are nothing short of revolutionary. Many existing NITs exhibited prognostic performance comparable to, if not superior to, liver histology. Notably, the Vibration-Controlled Transient Elastography (VCTE)-based Agile 3+ and Agile 4 scores stood out, boasting time-dependent area under the curve values nearing 90%. Furthermore, a 20% or greater change in liver status measurement translated into significant alterations in the incidence of liver-related events, validating NITs as effective monitoring tools.

Professor Wong emphasizes the transformative impact of these findings on the field. With growing evidence supporting the efficacy of NITs in predicting liver-related events and monitoring disease progression, the need for liver biopsy for prognostication diminishes. As regulatory bodies consider NITs as surrogate endpoints, patients stand to benefit from reduced reliance on invasive procedures, both in research and routine clinical care.

In conclusion, Professor Wong’s study heralds a new era in liver disease management, where noninvasive tests serve as reliable indicators of prognosis. With these insights, medical practitioners can navigate the complexities of MAFLD with greater confidence and precision, ultimately improving patient outcomes.

We extend our heartfelt congratulations to Professor Wong and his team for their remarkable contribution to the field. Stay tuned for more enlightening discussions on cutting-edge medical research.

Dear Medical Colleagues,

In the ever-evolving landscape of hepatocellular carcinoma (HCC) management, staying abreast of the latest advancements is paramount. Fortunately, the recent HCC Day 2024 provided an invaluable platform for knowledge exchange, featuring esteemed international experts who shared groundbreaking insights and strategies in the fight against HCC.

We are excited to announce that the video content from this exceptional event is now available for viewing. Delve into a wealth of expertise and innovation by accessing the recordings at HCC Day 2024 webcast.

Here are just a few highlights from the keynote presentations:

1. Selecting Systemic Therapy for HCC – Dr. A. Saborowski offers invaluable guidance on navigating the complex landscape of systemic therapy selection, providing practical insights for optimizing patient outcomes.
2. TACE with I/O for HCC – Dr. R. Lencioni explores the promising frontier of combining transarterial chemoembolization (TACE) with immunotherapy, shedding light on novel approaches to HCC treatment.
3. Combining Chemotherapy and Immunotherapy for Biliary Tract Cancer – Dr. K. Kelley shares groundbreaking research on the integration of chemotherapy and immunotherapy as a first-line approach for biliary tract cancer, offering new hope for patients facing this challenging disease.
4. Systemic Therapies in Phase 2 to Treat HCC – Dr. R. Finn provides invaluable insights into emerging systemic therapies in phase 2 trials, highlighting potential game-changers in the field of HCC management.
5. Preventing HCC Recurrence after Curative Therapy – Dr. P. Galle presents strategies for preventing HCC recurrence following curative therapy, addressing a critical aspect of long-term patient care.

Whether you’re a seasoned oncologist, a hepatologist, or a healthcare professional with an interest in HCC, these presentations are a must-watch. Gain access to cutting-edge research, clinical strategies, and expert perspectives that can inform and enhance your practice.

Don’t miss out on this unparalleled opportunity to expand your knowledge and elevate patient care. Click here to access the full spectrum of presentations from HCC Day 2024, thanks to Klewel audiovisual, streaming and webcasting services.

Yours in advancing HCC care,

Professor Jean-François Dufour / NASH Foundation

/

You can find the talks of the International NASH Symposium – 2023 a pivotal year for NASH now on our YouTube Channel.

We welcome you to the International NASH Symposium 2023 in Bern, Switzerland and online on the 30th November 2023!

Have a look at the agenda or register here to attend online. if you want to join the event in Bern please send us an email. Looking forward seeing you all soon!